NLRP3 and breast cancer: In view of the fact that TNBC and HR+ subtypes are immunohistochemically distinct [138,139,140,141,142], it has been noticed that after 24 h of TQ treatment, 50 μM TQ upregulated NLRP3 followed by a completely abolished expression at 100 μM in PBMCs of HR+ BC (Figure 1D).